Evidence map›Paper›PMID 25038135›Full record

ArticleJournal of medical microbiology2014

Outbreaks due to Mycobacterium abscessus subsp. bolletii in southern Brazil: persistence of a single clone from 2007 to 2011.

Luciana de S Nunes, Ludmila F Baethgen, Marta O Ribeiro, Cássia M Cardoso, Fernanda de Paris, Simone M M De David, Marlei G da Silva, Rafael S Duarte, Afonso L Barth

Abstract read
In one paragraph

Article in Journal of medical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Drug susceptibility profiles ofJournal of medical microbiology · 2025
    Article
  3. Article
  4. Pulmonary non-tuberculous mycobacterial infections: current state and future management.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  5. Article
  6. Antimicrobial agents and chemotherapy · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luciana de S NunesLaboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.
Ludmila F BaethgenLaboratório Central de Saúde Pública, Porto Alegre, Brazil.
Marta O RibeiroLaboratório Central de Saúde Pública, Porto Alegre, Brazil.
Cássia M CardosoLaboratório Central de Saúde Pública, Porto Alegre, Brazil.
Fernanda de ParisUnidade de Pesquisa Biomédica, Serviço de Patologia Clínica, Hospital de Clínicas de Porto Alegre (HCPA), Brazil.
Simone M M De DavidLaboratório Central de Saúde Pública, Porto Alegre, Brazil.
Marlei G da SilvaInstituto de Microbiologia, Universidade Federal do Rio de Janeiro (UFRJ), Brazil.
Rafael S DuarteInstituto de Microbiologia, Universidade Federal do Rio de Janeiro (UFRJ), Brazil.
Afonso L BarthLaboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.

Funding

Innovative approaches for tuberculosis control in BrazilU2RTW006883 · FIC · FEDERAL UNIVERSITY OF RIO DE JANEIRO · PI LAPA E SILVA, JOSE ROBERTO · 2005 to 2015
$3.5M
FIC NIH HHS 5 U2R TW006883-02FIC NIH HHS U2R TW006883
6 · The paper itself

Abstract

Outbreaks associated with rapidly growing mycobacteria (RGM) have been increasingly reported worldwide, including in Brazil. Among the RGM, the Mycobacterium abscessus complex is the most pathogenic and related to multidrug resistance. The aim of this study was to evaluate the antimicrobial susceptibility and molecular profile of RGM isolates involved in new postsurgical infection outbreaks in Brazil since 2007. Of the 109 cases reported in the state of Rio Grande do Sul between 2007 and 2011, 43 (39 %) had confirmed mycobacterial growth in culture. Clinical isolates were obtained from biopsy specimens or abscess aspirates. PRA-hsp65 restriction pattern identified the isolates as M. abscessus type 2, and partial rpoB sequencing confirmed the identification as M. abscessus subsp. bolletii. All isolates were susceptible to amikacin and resistant to ciprofloxacin, doxycycline, sulfamethoxazole, moxifloxacin and tobramycin. Most isolates (72 %) were fully susceptible to cefoxitin but six isolates (14 %) were fully resistant to clarithromycin. The latter differed from the susceptibility profiles of the previously described BRA100 clone from other Brazilian regions. Nevertheless, pulsed-field gel electrophoresis analysis revealed that these isolates belonged to a single BRA100 clone. In conclusion, our study reports the persistence of an emergent single and highly resistant clone of M. abscessus subsp. bolletii for several years even after national implementation of infection control measures.

Indexed as

Disease OutbreaksMolecular TypingAnti-Bacterial AgentsBacterial ProteinsBrazilChaperonin 60DNA-Directed RNA PolymerasesElectrophoresis, Gel, Pulsed-FieldGenotypeHumansMicrobial Sensitivity TestsMolecular EpidemiologyMycobacteriumMycobacterium Infections, NontuberculousPolymorphism, Restriction Fragment LengthSequence Analysis, DNAAnti-Bacterial AgentsBacterial ProteinsChaperonin 60DNA-Directed RNA Polymerasesheat-shock protein 65, MycobacteriumRNA polymerase beta subunit

Identifiers

PMID25038135
PMCPMC7304884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.